Literature DB >> 29600024

Does VALIDATE-SWEDEHEART invalidate the use of bivalirudin in myocardial infarction?

Caroline Ong1, Sripal Bangalore1.   

Abstract

Entities:  

Year:  2018        PMID： 29600024      PMCID： PMC5863208          DOI： 10.21037/jtd.2017.12.100

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  20 in total

1.  Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.

Authors:  Adnan Kastrati; Franz-Josef Neumann; Stefanie Schulz; Steffen Massberg; Robert A Byrne; Miroslaw Ferenc; Karl-Ludwig Laugwitz; Jürgen Pache; Ilka Ott; Jörg Hausleiter; Melchior Seyfarth; Michael Gick; David Antoniucci; Albert Schömig; Peter B Berger; Julinda Mehilli
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

2.  Temporal trends in and factors associated with bleeding complications among patients undergoing percutaneous coronary intervention: a report from the National Cardiovascular Data CathPCI Registry.

Authors:  Sumeet Subherwal; Eric D Peterson; David Dai; Laine Thomas; John C Messenger; Ying Xian; Ralph G Brindis; Dmitriy N Feldman; Shaun Senter; Lloyd W Klein; Steven P Marso; Matthew T Roe; Sunil V Rao
Journal:  J Am Coll Cardiol       Date:  2012-05-22       Impact factor: 24.094

3.  Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction.

Authors:  Matthias Schwenkglenks; Toby J Toward; Stephanie Plent; Thomas D Szucs; Daniel J Blackman; Andreas Baumbach
Journal:  Heart       Date:  2012-02-07       Impact factor: 5.994

4.  2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Ezra A Amsterdam; Nanette K Wenger; Ralph G Brindis; Donald E Casey; Theodore G Ganiats; David R Holmes; Allan S Jaffe; Hani Jneid; Rosemary F Kelly; Michael C Kontos; Glenn N Levine; Philip R Liebson; Debabrata Mukherjee; Eric D Peterson; Marc S Sabatine; Richard W Smalling; Susan J Zieman
Journal:  Circulation       Date:  2014-09-23       Impact factor: 29.690

5.  Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention.

Authors:  Freek W A Verheugt; Steven R Steinhubl; Martial Hamon; Harald Darius; Philippe Gabriel Steg; Marco Valgimigli; Steven P Marso; Sunil V Rao; Anthony H Gershlick; A Michael Lincoff; Roxana Mehran; Gregg W Stone
Journal:  JACC Cardiovasc Interv       Date:  2011-02       Impact factor: 11.195

6.  Practice Patterns and In-Hospital Outcomes Associated With Bivalirudin Use Among Patients With Non-ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention in the United States.

Authors:  Eric A Secemsky; Ajay Kirtane; Sripal Bangalore; Ion S Jovin; Dhavalkumar Patel; Enrico G Ferro; Neil J Wimmer; Matthew Roe; David Dai; Laura Mauri; Robert W Yeh
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2017-09

7.  Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.

Authors:  Adeel Shahzad; Ian Kemp; Christine Mars; Keith Wilson; Claire Roome; Rob Cooper; Mohammed Andron; Clare Appleby; Mike Fisher; Aleem Khand; Babu Kunadian; Joseph D Mills; John L Morris; William L Morrison; Shahzad Munir; Nick D Palmer; Raphael A Perry; David R Ramsdale; Periaswamy Velavan; Rod H Stables
Journal:  Lancet       Date:  2014-07-04       Impact factor: 79.321

8.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).

Authors:  Borja Ibanez; Stefan James; Stefan Agewall; Manuel J Antunes; Chiara Bucciarelli-Ducci; Héctor Bueno; Alida L P Caforio; Filippo Crea; John A Goudevenos; Sigrun Halvorsen; Gerhard Hindricks; Adnan Kastrati; Mattie J Lenzen; Eva Prescott; Marco Roffi; Marco Valgimigli; Christoph Varenhorst; Pascal Vranckx; Petr Widimský
Journal:  Eur Heart J       Date:  2018-01-07       Impact factor: 29.983

9.  Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.

Authors:  Sripal Bangalore; Bora Toklu; Anupam Kotwal; Alexander Volodarskiy; Sahil Sharma; Ajay J Kirtane; Frederick Feit
Journal:  BMJ       Date:  2014-11-11

10.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).

Authors:  Marco Roffi; Carlo Patrono; Jean-Philippe Collet; Christian Mueller; Marco Valgimigli; Felicita Andreotti; Jeroen J Bax; Michael A Borger; Carlos Brotons; Derek P Chew; Baris Gencer; Gerd Hasenfuss; Keld Kjeldsen; Patrizio Lancellotti; Ulf Landmesser; Julinda Mehilli; Debabrata Mukherjee; Robert F Storey; Stephan Windecker
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983
View more
  1 in total

1.  Effect of the WeChat Platform Health Management and Refined Continuous Nursing Model on Life Quality of Patients with Acute Myocardial Infarction after PCI.

Authors:  Meifang Xu; Xiaofang Yang; Lin Liu; Yunlang Dai; Mingzhu Xu; Shi Lin
Journal:  J Healthc Eng       Date:  2021-11-29       Impact factor: 2.682
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.